Quality of Life Important in Assessing Cancer TherapiesQuality of Life Important in Assessing Cancer Therapies

Dr Gerald Chodak discusses a new study that examines the effectiveness of enzalutamide in metastatic castration-resistant prostate cancer, emphasizing the importance of the patient's quality of life. Medscape Urology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

UCLA researchers have discovered  genetic similarities between the adult stem cells responsible for maintaining and repairing epithelial tissues — which line all of the organs and cavities inside the body — and the cells that drive aggressive epithelial cancers. Their findings could bring about a better understanding of how ag gressive, treatment-resistant cancers develop and progress, and could eventually lead to new drugs for a range of advanced epithelial cancers such as lung, prostate and bladder cancers. The study, led by senior authors Owen Witte and Thomas Graeber, both of the  UCLA E...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSION: Our findings provide evidence of the clinical relevance, significance and regulation of HSD17B2 in prostate cancer progression, which might provide new strategies for clinical management by targeting the functional silencing mechanisms of HSD17B2. PMID: 30228209 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: Available online 10 September 2018Source: Seminars in Cancer BiologyAuthor(s): Nicholas Howard, Marco Clementino, Donghern Kim, Lei Wang, Angela Verma, Xianglin Shi, Zhuo Zhang, Robert S. DiPaolaAbstractProstate cancer is the most prevalent type of cancer in men. The etiology of prostate cancer development and the mechanisms underlying androgen-independent progression remains to be further investigated. There are many known targets for prostate cancer therapy including the androgen receptor (AR) axis, but resistance eventually develops in advanced disease suggesting the need to better understand mechanism...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Our result demonstrated the in vitro and in vivo antimetastatic effect of pan-PI3K inhibitor ZSTK474 on prostate cancer DU145 cells, suggesting the potential application in prostate cancer patients. PMID: 30205797 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research
Alpha Tau Medical said today it raised $29 million in a private funding round to help support its alpha radiation cancer therapy technology. The round was led by Israeli private equity firm Shavit Capital and joined by global equity crowdfunding platform OurCrowd.com and Medison Pharma venture capital arm Medison Ventures, the Israel-based company said. The round was also joined by Apax Partner founds Ronald Cohen and Alan Patricof, Alpha Tau said. “We are confident that Alpha Tau’s ground-breaking technology can be a game changer in the treatment of cancer. Importantly, under the guidance of an exper...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Funding Roundup Alpha Tau Medical Source Type: news
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is driven by the lack of therapeutic regimens capable of generating durable responses in the setting of extreme tumor heterogeneity on the genetic and cell biological levels. Here, we review available prostate cancer model systems, the prostate cancer genome atlas, cellular and functional heterogeneity in the tumor microenvironment, tumor-intrinsic and tumor-extrinsic mechanisms underlying therapeutic resistance, and technological a...
Source: Genes and Development - Category: Genetics & Stem Cells Authors: Tags: Cancer and Disease Models Reviews Source Type: research
LOS ANGELES– Stand Up To Cancer (SU2C), a division of the Entertainment Industry Foundation (EIF), is proud to announce that the Hollywood community is rallying together yet again to support the sixth biennial televised fundraising special. CBS will donate one hour of commercial-free primetime to broadcast the event on Friday, Sept. 7  from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT). Mahershala Ali, Kathy Bates, Katie Couric, Jennifer Garner, Tony Hale, Marg Helgenberger, Ed Helms, Ken Jeong, Marlee Matlin, Matthew McConaughey, Maria Menounos, Jillian Michaels, Trevor Noah, Dak Prescott, Italia Ricci, ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Only CBS Stand Up To Cancer Source Type: news
Veterans who seek care for low-risk prostate cancer receive more imaging that...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Multiparametric MRI aids in prostate cancer follow-up SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment MRI-based risk model improves prostate cancer detection
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
(University of East Anglia) A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon.Using nanoparticles to get drugs directly into a tumor is a growing area of cancer research. The technology developed at UEA is the first of its kind to use nanoparticles to deliver two drugs in combination to target cancer cells. The therapy has been shown to make breast cancer and prostate cancer tumors more sensitive to chemotherapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
CONCLUSIONS: Targeted MRI/TRUS fusion-guided focal HIFU allows local tumor ablation, but is not free from limitations. The procedure has good functional outcomes and a quick recovery. Multicenter trials with more patients are required to determine the procedure´s role in the prostate cancer therapy algorithm. PMID: 30093211 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hematology | Prostate Cancer | Study | Urology & Nephrology